• The CCPA limits data flows to brands and marketers, and CPRA amendments are set to take effect January 1, 2023
• CPRA and CCPA provisions include the right to opt-out of data sharing and sale, as well as the right to data deletion
• Consumer data is critical to branding and advertising strategies
• Reklaim provides an ecosystem that equips marketers with fully compliant, consumer-verified data sets while rewarding consumers for sharing information

With the aim of protecting consumers, the California Consumer Privacy Act (“CCPA”) and amendments provided by the California Privacy Rights Act (“CPRA”) are gradually transforming the advertising landscape by limiting data flows to brands and advertisers. Reklaim (TSX.V: MYID) (OTCQB: MYIDF) is firmly positioned to fill the void with a privacy-compliant desktop and mobile identity ecosystem that provides relevant datasets to marketers while rewarding consumers for sharing their data. Data fuels the company’s need to market activities for brands and advertisers. However, options are gradually decreasing due to privacy laws restricting information flow of information to the market. One such law is the CCPA, which took effect on January 1, 2020, and is set to be amended by the CPRA on January 1, 2023 (https://ibn.fm/UbGB0). The CCPA’s initial provisions give consumers the right to know what data is collected, why it is collected, if it is sold and what party bought the information. They also offered the right to delete this data. The CPRA adds two additional provisions: the right to correct inaccurate personal information and the right to limit the use and disclosure of sensitive personal data. The CCPA and subsequent CPRA amendments impose these obligations on businesses, service providers, contractors and third parties. Consequences for non-compliance include penalties of up to $7,500 per intentional violation, $2,500 per unintentional violation and statutory damages of up to $750 per consumer per incident. California is the world’s sixth-largest economy, ahead of Italy and closely behind France (https://ibn.fm/nzX82), making it a highly lucrative jurisdiction for brands and advertisers. In addition to severely limiting marketing activities in the United States, similar laws enacted in other countries threaten to greatly reduce the impact of advertising campaigns worldwide (https://ibn.fm/QLTnl). Reklaim is strongly positioned to support brands with fully consensual, consumer-verified data through an ecosystem that rewards users for sharing their data while providing verified datasets advertisers can access for a fee. Besides being fully compliant, Reklaim’s platform offers more relevant and higher-quality data, because consumers on the platform actively provide and choose to share their information. According to Fortune Business Insights, the global customer data platform market was valued at $1.42 billion in 2022 and is expected to reach $6.94 billion by 2029, expanding at a CAGR of 25.4% over the forecast period (https://ibn.fm/ZCUUC). As demand for consumer data continues to rise amid legislative restrictions, Reklaim provides valuable, transparent and high-quality solutions that benefit both sides of the consumer data market. For more information, visit the company’s website at www.ReklaimYours.com. NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• CNS Pharmaceuticals is focused on advancing its clinical development for the Berubicin drug candidate in order to bring meaningful treatment to GBM patients
• GBM, which has a low survival rate, has limited treatment options when it progresses after first-line therapy
• The company is looking to find a solution with Berubicin and is currently evaluating this drug candidate in a potentially pivotal global study
• CNS’s ongoing R&D efforts are boosted by its strong cash position; in its Q2 2022 report, the company announced it had cash of about $9.0 million and working capital of $10.5 million

CNS Pharmaceuticals (NASDAQ: CNSP), an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system (“CNS”) cancer, started 2022 on a high, closing an $11.5 million private placement whose net proceeds the company intended to deploy toward funding its clinical trials and preclinical programs as well as other research and development (“R&D”) activities and general corporate purposes. The additional funding not only boosted the company’s R&D efforts but also enhanced its cash position, as reflected in its subsequent financial reports (https://ibn.fm/GK93f). In its report for the three months ended June 30, 2022 (“Q2 2022”), CNS Pharmaceuticals had cash and cash equivalents of about $9.0 million and working capital of $10.5 million (https://ibn.fm/UiG9a). And although the figure represented a drop from about $12.4 million and $13.7 million, respectively, recorded in the period ended March 31, 2022 (“Q1 2022”) (https://ibn.fm/ycZXd), the company spent 46% more on R&D in Q2 2022 than in Q1 2022. (Its R&D expenditure in Q2 2022 was $2.2 million.) CNS Pharmaceuticals expects its cash on hand and proceeds from the placement to fund its operations into Q1 2023. The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for Glioblastoma Multiforme (“GBM”), according to CNS Pharmaceuticals CEO John Climaco. The company’s focus and priorities, Climaco emphasized, are firmly anchored in the advancement of its clinical development for its drug candidate Berubicin with the aim of bringing meaningful treatment to GBM patients. And as he separately told attendees at the recently held H.C. Wainwright 24th Annual Global Investment Conference, this focus is driven by a significant unmet clinical need, especially given that recurrent GBM does not have “an approved therapy anywhere in the world” (https://ibn.fm/ciFue). For GBM patients, this unmet need causes anguish that often culminates in death. A 2021 study, for instance, notes, “Once tumors progress after first-line therapy, treatment options are limited, and the management of recurrent GBM remains a challenge” (https://ibn.fm/4ZfEE). Another, a 2015 study, underlines that recurrence is, unfortunately, inevitable, with its management unclear and case-dependent (https://ibn.fm/DRKYF). These characteristics have meant that GBM remains one of the most aggressive primary brain tumors, with a grim prognosis. Data from the American Cancer Organization shows that GBM has the least 5-year relative survival rate of the various common adult brain and spinal cord tumors in the list. For example, among 20- to 44-year-old patients, the survival rate stands at 22%. This figure drops to 9% among adults aged between 45 and 54 and 6% among those between 55 and 64. In comparison, anaplastic astrocytoma, the condition with the second lowest survival rate in the list, has higher survival rates of 58%, 29%, and 15%, respectively, across the three age categories (https://ibn.fm/IR0ko). The condition’s aggressiveness is further concretized by the fact that over 10,000 patients succumb to GBM annually in the United States, where 13,000 people are diagnosed with GBM every year the average length of survival for GBM patients is estimated to be only eight months. (https://ibn.fm/hUVew). With the survival rate and mortality statistics for GBM remaining virtually unchanged for decades, according to the National Brain Tumor Society, CNS Pharmaceuticals is working hard to find a solution. The company is relying on Berubicin, a novel anthracycline whose mechanism of action is inhibiting the topoisomerase II enzyme that causes cell replication and is abundantly found in tumor cells. CNS Pharmaceuticals has observed that the drug, which appears, based on limited clinical data, to cross the blood-brain barrier, is selectively absorbed in cancerous cells and tissue in the brain. The Berubicin drug candidate solves a problem that has long dogged cancer research for years. Although anthracyclines have existed for the past six decades, they could not cross the blood-brain barrier. CNS Pharmaceutical’s drug candidate, therefore, is the first anthracycline to appear to cross this critical barrier. The company is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent GBM. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• The upcoming COP27 Conference in Egypt will dictate the world’s latest measures designed to adhere to 2015’s Paris Agreement
• With the world increasingly focused on containing global warming and subduing household greenhouse gas emissions, has taken on increasing relevance
• Within the U.S., households account for 20% of total carbon emissions – with U.S. household emissions alone surpassing those of Germany as a whole
• GeoSolar Technologies’ revolutionary SmartGreen(TM) Home system has been designed to power homes through a mix of renewable energy sources – effectively reducing the average home’s carbon footprint to near zero

When the upcoming United Nation’s Climate Change Conference, better known as ‘COP27’, kicks off in Egypt’s Sharm El-Sheikh on November 6th, it will do so amidst some of the most perilous environmental conditions the world has ever witnessed. Faced with a growing energy crisis, record greenhouse gas concentrations, and increasing extreme weather events, politicians will be at pains to deliver action on an array of issues critical to tackling the ongoing climate emergency. Ranging from urgently reducing greenhouse gas emissions, through to building resilience and adapting to the inevitable impacts of climate change, all whilst delivering on commitments to finance climate action in developing countries, conference attendees will be asked to commit to a wide array of initiatives to halt global warming on its tracks. With 40 percent of greenhouse gas (“GHG”) emissions originating from real estate, measures to decarbonize households will form an increasing priority within the global political agenda – with tackling US household emissions foremost on that list (https://ibn.fm/8bSbt). A comprehensive study encompassing 93 million individual households within the United States found that residential energy usage accounts for as much as 20 percent of GHG emissions in the United States (https://ibn.fm/A7ydM). Putting that figure into perspective – if the U.S. housing sector’s emissions were to be considered as a country, that country would represent the world’s sixth largest GHG emitter, comparable to the entirety of Brazil’s emissions and ranking significantly higher than those of Germany. Perhaps more ominously, by 2025 the United States will add an estimated 70-129 million residents and 62-105 million new homes, growing the urgent need to reduce emissions across the US housing sector. Consequently, and despite U.S. homes becoming increasingly energy efficient in recent years, U.S. household energy use and consequently, the sector’s GHG emissions, have failed to reduce as a by-product of demographic trends, necessitating the employment of additional measures to arrest the incessant growth in carbon dioxide emissions. GeoSolar Technologies (“GST”), a Colorado-based climate technology company, has sought to cater to this increasingly urgent requirement. Through the introduction of its proprietary SmartGreen(TM) Home system – an environmentally friendly, renewable energy focused technology designed to harness energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels, GeoSolar are focused to tackle the astounding thirty percent of global greenhouse gases generated by households every year. Moreover, and during a time of increasingly elevated electricity costs, the company has illustrated how the average GeoSolar-powered home could result in a negligible carbon footprint, with homeowners disbursing less than $100 per annum in utility bills (https://ibn.fm/QBDD9). Solar, wind, and hydroelectric power have long been renowned as popular and well accepted renewable energy sources, with a number of these achieving grid cost parity relative to more conventional energy sources in different jurisdictions. Whilst GeoSolar have made use of a variety of conventional forms of renewable energy within its home energy systems, it has also looked towards adopting a more holistic approach by harnessing other, more unconventional energy sources, including the likes of geothermal energy; effectively, tapping into heat generated from the Earth’s core to generate electricity (https://ibn.fm/jRt9R). The geothermal energy is than used to power heat pumps, with the latter employed to warm houses rather than having households rely on more conventional air-conditioning and gas furnace systems. With the world’s climate increasingly seen to be teetering on a precipice, global coordinated action will be essential in terms of preserving the environment as we see it today. Given the important role controlling household emission levels will play within this initiative, GeoSolar Technologies’ revolutionary SmartGreen(TM) Home system as well as its innovative use of renewable energy sources could not have come at a better time. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• The United States is still the world’s largest economy and largest importer and exporter of goods and services – with strong ties to Mexico and Canada
• Mexico has reached number one as a US trade partner, with a value of $520.12 billion during the first eight months of 2022, followed by Canada
• Freight Technologies’ cloud-based marketplace, Fr8App, is simplifying Over-The-Road (“OTR”) trade and reducing the carbon footprint in the industry by directly matching OTR shippers with qualified carriers and provides 24/7 live tracking, quick pay, and driver rating features
• The company is building strategic relationships with key customers across trade industries, expanding its customer base to provide its all-in-one solution for shippers with more reliable results and lower costs

Trade is vital to America’s prosperity as the world’s largest economy and largest importer and exporter of goods and services. Trade fuels economic growth, supports good jobs, raises living standards, and helps provide families with affordable goods and services. For the first time since January of this year, Mexico overtook Canada as the number one trade partner of the United States in August, increasing trade to $520.12 billion through the first eight months of the year, according to Census Bureau data analyzed by World City (https://ibn.fm/2YU7w). The most popular point for commercial truck crossings between the United States and Mexico is Laredo, Texas, which saw an increase of 12.8%, equivalent to 246,019 vehicles during August – ranking the port number two among the 450 ports, seaports, and border crossings between the United States and Mexico. The increase has brought the total number of truck crossings in Laredo to 2.7 million, an increase of 8.9% year to date. Some of the biggest challenges experienced by freight carriers since the COVID-19 pandemic include global supply chain disruptions, increased ocean freight rates, and logistics challenges – but demand for importing and exporting is as strong as ever. Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process and provides a platform for B2B cross-border shipping across the USMCA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility, and simplicity for the once-complex process of international OTR shipping. Fr8Tech is leveraging its technology to help improve their customers’ operational efficiency and security while reducing its carbon footprint by optimizing empty miles and reducing paper consumption. Fr8App is a cloud-based marketplace that combines all aspects of a centralized control center into one platform – directly matching cross-border shippers throughout Mexico, Canada, and the United States with available carriers and drivers for their loads and capable of tracking status from start to finish. Powered by artificial intelligence and machine learning, Fr8App is the company’s B2B marketplace offering a real-time portal to connect shippers with qualified carriers. The Fr8App comes with 24/7 live tracking, quick pay, and driver ratings to make the process faster, more secure, and at the best pricing possible. The commercial trucking market is full of inefficiencies that create problems for both shippers and carriers equally, including a lack of transparency in pricing, inefficient matching, low technological penetration, and complexity of cross-border trades – Fr8App automates the process, making it more efficient and reducing logistic costs while improving security. The company is building strategic relationships with key players in the transportation industry, allowing faster growth of its customer base with enterprise accounts. With major imports and exports stemming from technology and other goods and services, the integration of these companies is allowing for Fr8Tech to provide an all-in-one solution for the inefficiencies these customers face in the transportation industry today by connecting the US, Mexico, and Canadian Marketplace (“USMCA”) with a single shipping solution. For more information, visit the company’s website at www.Fr8Technologies.com. NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT Corporate Communications IBN (InvestorBrandNetwork) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

• Odyssey Health is a medical company specializing in the development of unique, life-saving medical products that provide solutions to unmet clinical needs, one of which is concussion, which currently does not have an FDA-approved drug
• The company has developed the PRV-002 drug candidate, which is designed to be administered intranasally where pre-clinical results have shown to be effective in treating a concussion within 30 minutes of administration
• Through its drug candidate, Odyssey hopes to reduce the risks and potential for long-term consequences associated with concussions

Up until Olympic gold medalist Katie Weatherston was forced into retirement following a series of mild traumatic brain injuries (“mTBIs”) or concussions, she and her professional career were blossoming. As a member of the Canadian national team, Katie won a gold medal in the ice hockey tournament at the 2006 Olympic Games in Turin, Italy. In 2007, she again was a gold medalist at the 2007 IIHF Ice Hockey Women’s World Championship held in Canada; a year later, at the IIHF Championship tournament held in China, she would go on to win a silver medal (https://ibn.fm/LVU6f). Indeed, Weatherston’s career comprised moments most athletes only dream of; but during an interview published in 2013 on CTV Ottawa Morning Live’s YouTube channel (https://ibn.fm/6AVQg), she asked whether it was worth the life-long consequences she could have, to which she ruefully answered, “Probably not.” The figurative beginning of the end, at least career-wise, started in 2005 when she flew over the handlebars during a bike race with her team. Then in 2006, she was hit from the back and went head first into the boards at a training camp; the team doctor cleared her after assessing her for a concussion, allowing her to get back into the game. But she suffered two more blows to the head. Within the next few days, Katie developed concussion symptoms and was eventually confirmed to have sustained a concussion, forcing her out of the game for several months. Fortunately, she eventually got back to doing what she loved, albeit for a short period, until a minor fall gave her whiplash in 2008 (https://ibn.fm/MQnOm). For the 16 years since the 2006 series of injuries, Katie told CBC in an interview, she has struggled with daily headaches, chronic exhaustion, and the sensation of her ears popping. And to cope, she has had to seek medical care in the form of, among others, physiotherapy and chiropractor appointments, which require her to fork out CA$30,000 to CA$40,000 a year. Katie had been left with prolonged or persistent post-concussion syndrome (“PPCS”) (https://ibn.fm/Caq8o). Although concussion holds the potential to upend life, causing lingering symptoms that complicate everyday activities, it currently does not have an FDA-approved treatment. This is despite the fact that between 1.6-3.8 million concussions occur in the United States every year (https://ibn.fm/N0HT1), with 10-20% of these cases likely to lead to PPCS (https://ibn.fm/cSgTP). In recognizing this gap, Odyssey Health (OTC: ODYY), a medical company developing unique, life-saving medical products that provide solutions to unmet clinical needs, embarked on the development and evaluation of PRV-002, a novel compound for the treatment of concussion. Through in-vivo animal testing, PRV-002 has been shown to have anti-inflammatory, antioxidant, and antiedematous properties that ensure it eliminates the immediate consequences of a concussion, namely swelling, oxidative stress, and inflammation in the brain while restoring proper blood flow. Additionally, animal models of concussion have demonstrated that PRV-002 reduces behavioral pathology linked to mTBI symptoms such as motor/sensory performance, anxiety, and memory impairment. Odyssey recently completed its registered Phase I trial, which was segmented into Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) portions, both of which evidenced that PRV-002 is safe and well-tolerated when administered to healthy subjects (https://ibn.fm/qFt73). Next, the company is planning a Phase II trial that will evaluate the efficacy of the drug candidate in concussed patients. The study will initially be domiciled in select military sites where personnel are prone to sustaining concussions during training. Designed to be delivered via the Odyssey’s novel intranasal drug delivery device, the drug candidate is meant to be administered within minutes of a concussion episode, allowing it to reverse the effects of the blow or jolt to the head. This immediate action is attributable to the intranasal delivery, which deposits the dry powder to the upper chamber of the nasal cavity for onward travel to the brain via the cranial nerve, and the drug’s lipophilic properties that enable it to cross the blood-brain barrier. Once approved, PRV-002 is poised to potentially reduce the risks posed by concussions, which have impacted the lives of many professional athletes, some of whom, like Katie Weatherston, have been forced into retirement and still have lingering symptoms such as balance problems, difficulty focusing their gaze, dizziness, depression, and chronic exhaustion (https://ibn.fm/aRX4f). For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Flora Growth signed a definitive agreement with FGH to acquire 100% of all issued and outstanding shares by way of a statutory plan of agreement
• The deal is expected to close in December following the presentation of the agreement to shareholders; the acquisition will open Flora to the German and EU medical markets, increasing the company’s international revenue and providing essential distribution to German pharmacies and a growing wholesale market
• FGH’s acquisition adds to Flora’s expanding list of subsidiaries which currently comprise Vessel Brand Inc. and JustCBD, among others, and it is expected to deliver at least $3 million in annualized cost synergies within the first year
• Luis Merchan, Flora’s Chairman and CEO, has noted that he believes the company has a path to profitability that few global cannabis companies can achieve, and the acquisition shows Flora’s commitment to achieving this profitability
• The acquisition also highlights the company’s understanding of the global cannabis space, the opportunities therein, and what it would take for it to become the undisputed market leader

Flora Growth (NASDAQ: FLGC), an internationally focused cannabis builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives, is looking to grow its product portfolio and expand its market reach with the proposed acquisition of Franchise Global Health Inc. (“FGH”), a multi-national operator in the medical cannabis and pharmaceutical industry (https://ibn.fm/Vz1cd). With principal operations in Germany, FGH’s acquisition will open Flora up to the German and European Union (“EU”) medical markets, which its management notes will significantly increase the company’s commercial international revenue. Flora signed a definitive agreement with FGH to acquire 100% of all issued and outstanding shares by way of a statutory plan of arrangement. The company expects to close the deal in December following the presentation of the agreement to shareholders. Completion of the agreement will be subject to certain closing conditions customary for transactions of this nature, including, but not limited to, approval by the Supreme Court of British Columbia. FGH will add to Flora’s expanding list of subsidiaries comprising Vessel Brand Inc. and JustCBD, among others. It is also expected to deliver at least $3 million in annualized cost synergies within the first year, mainly in reduced corporate administrative expenses. “Through this proposed acquisition, we are connecting our commercial infrastructure and medical cannabis product portfolio to the German and EU medical markets while gaining direct access to European pharmaceutical distributions,” noted Luis Merchan, Flora’s Growth’s Chairman and CEO. “We believe Franchise will significantly increase our commercial international revenue and provide essential distribution to German pharmacies and a growing wholesale market,” he added. In August, Flora released its financial results for the first half of the 2022 financial year (“H1 2022”). Most notably, the company delivered on its promise to double revenue compared to H2 2021, lauding the integration of both Vessel and JustCBD. In addition, the company’s management expressed its confidence in maintaining the current trajectory to deliver its full-year guidance due to continued growth in its House of Brands. “We continue to prudently manage our overhead and working capital as we expect to improve profitability going forward,” noted Mr. Merchan. “We believe we have a path to profitability that few global cannabis companies can achieve in this difficult moment. The execution of our key initiatives is a testament to our team’s ability to deliver on plan. We will continue to execute as we focus on profitability and long-term value creation,” he added (https://ibn.fm/3LNn5). FGH’s acquisition is poised to bolster Flora’s profitability while strengthening its market presence. The move is also a testament to the company’s commitment to its vision of global market dominance. In addition, it reflects its management’s competence and understanding of what is required for the company to grow and achieve its short-term and long-term goals. Still, most importantly, it shows Fora’s understanding of the global cannabis space, the opportunities therein, and what it would take to become the undisputed market leader. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• The California Department of Cannabis Control (“DCC”) has reserved $20 million in funding for research prioritizing cannabis projects, including potency, health impact, medicinal use, legacy cannabis genetics, and industry health
• The medicinal and recreational cannabis market size in the US is anticipated to reach $33 billion in 2022, with a revenue outlook of $52.6 billion by 2026
• REZYFi Inc., through two wholly-owned subsidiaries, is positioned to be the first cannabis mortgage banker in the United States

The state of California Department of Cannabis Control has reserved $20 million in funding for research that prioritizes numerous cannabis topics, including potency, health impacts, medicinal use, legacy cannabis genetics, and the industry’s health. The DCC requires that research funded under the program be available publicly at no cost. The grant proposals will be accepted from November 1 through November 30, with winning research projects awarded in February 2023. The DCC research grants are making it possible for expansion in the cannabis industry through individualized research on topics that make an impact (https://ibn.fm/eWbjB). The medical and recreational cannabis market size in the United States is anticipated to reach $33 billion by the end of 2022, driven by the increase in the adult-use market. Retail sales are expected to reach $52.6 billion by 2026, according to the 2022 MJBiz Factbook (https://ibn.fm/TYDYL). The increase in the market can be attributed to consumer awareness and the legalization growing in states across the country – with four more states adding it to ballots for voters in November. There is an unmet need for cannabis companies looking for traditional banking opportunities. However, one company, REZYFi, is uniquely positioned as the first cannabis mortgage banker in the United States. REZYFi is a growth mortgage origination and specialized financing company servicing the needs of both traditional and non-traditional consumers and businesses – targeting licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects. REZYFi operates through two wholly-owned subsidiaries – REZYFi Lending and ResMac, Inc. REZYFi Lending leverages a wide network to offer options such as 15- to 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages. The company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the company’s launch of a high-margin cannabis division. ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. Through ResMac, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators. The company is leveraging its corporate strengths to enhance the current unmet needs of the market. REZYFi is using its experience, network of independent brokers, and proprietary technology to further advance its presence as one of the first cannabis mortgage bankers working on expanding licensing into all states. Through its unique offering, REZYFi is leading the industry with a diversified approach to the real estate lending sector, positioning itself to capitalize on growth in multiple verticals in years to come. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Lexaria just completed its HYPER-H21-4 human clinical hypertension study, posting a sustained drop in blood pressure in normally active hypertensive patients
• With the success of this study, the company is working towards an IND application to seek FDA approval for its patented DehydraTECH(TM)-enabled CBD capsule formulation.
• 47% of adults live with hypertension but only 24% of them have it under control
• With its DehydraTECH-CBD, Lexaria hopes to not only address the severe unmet patient need associated with hypertension but also tap into a market that is set to be valued at $34 billion by 2030

Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs, is looking to push the conversation about high blood pressure. Lexaria continues to move forward, most recently with the success in its latest human clinical study, HYPER-H21-4. The study may be the first to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (“CBD”) therapy using the company’s patented DehydraTECH(TM) technology (https://ibn.fm/cB22n). Since Lexaria began developing DehydraTECH in 2014, it has continued to strengthen and broaden the technology, exploring various areas including but not limited to the oral administration of antivirals, cannabinoids, vitamins, nicotine, and PDE5 inhibitors. In early 2021, it began dosing in its first human clinical study that assessed its DehydraTECH-enabled CBD capsule formulation. This would lay the groundwork for subsequent studies while also bolstering the company’s growing list of patents, which currently stands at 27, spread across the world, including the use of DehydraTECH-processed CBD for the treatment of heart disease (https://ibn.fm/Nd0Hf). Lexaria is working toward an Investigational New Drug (“IND”) application filing to seek U.S. Food and Drug Administration (“FDA”) approval. It hopes to build on the success of the studies so far to enhance its understanding of DehydraTECH-CBD for treating cardiovascular and other disease states beyond hypertension. Since its inception, Lexaria has been committed to addressing severe unmet patient needs. Hypertension has been one of the company’s main focus areas, with 47% of adults living with the condition, but only 24% have it under control. Through its research, it looks to address the condition, ultimately tapping into a market projected to post a CAGR of 3.4% between 2022 and 2030 to hit $34 billion in value (https://ibn.fm/3PBED). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Nearly a decade has passed since the Paris Accords established international cooperation on curbing fossil fuel pollutants believed to be responsible for adversely affecting the earth’s climate, and some agencies worry that not enough is happening to meet the accords’ goals
• Despite concerns about obstacles to renewable energy adoption, the same agencies note that investment in climate-friendly technologies is rising
• Correlate Infrastructure Partners is a U.S.-based company works with the commercial real estate industry to drive the transition to climate-friendly energy sources, helping clients analyze their utilities use, identifying ways to improve their ESG outcomes, and presenting funding opportunities to make cleaner energy an easy-to-afford part of their operational reality

Clean energy solutions innovator Correlate Infrastructure Partners (OTCQB: CIPI) is helping to move the needle on greenhouse gas reduction by advising the commercial real estate industry (companies that develop and rent out commercial building properties) on ways to transition to more climate-friendly utilities in their operations and on ways to make such transitions cost-effective. Worldwide, governments and private industries continue increasing their emphasis on clean energy adoption and reduction of their reliance on fossil fuels amid reports of an upward trend in extreme weather events and the insecurity people face in finding food and housing as a result (https://ibn.fm/CIT3i). Nearly a decade after nearly 200 international political governments and environmental activists arrived at a United Nations-sponsored agreement to limit pollutants believed responsible for a rising number of climate change-spawned extreme weather events, The United Nations is bemoaning a lack of effective progress on achieving the Paris Climate Accord goals (https://ibn.fm/r8zps). Uncertainty by European regulators over tax and subsidize the energy industry to quell high prices (https://ibn.fm/JDe5K) are likewise leading to fears that investment in renewable energy may decrease at a time when climate-friendly technologies are just beginning to take off on the continent (https://ibn.fm/6fbPU). The International Energy Agency (“IEA”), a Paris-based intergovernmental organization focused on policy advisement for energy security worldwide, reported earlier this year that global energy investment is expected to increase by 8 percent this year to $2.4 trillion. Those investments are primarily in clean energy operations, but the IEA report echoed the United Nations’ assessment that the pace is insufficient to address climate concerns (https://ibn.fm/vb7oA). Still, an Oct. 20 Scientific American report analyzing data from the IEA and other sources found reasons for optimism in the overall accomplishments of renewable energy transitioning, which would include the work Correlate Infrastructure and its subsidiaries are doing with their clients. Citing an IEA report that global carbon dioxide emissions associated with energy use are on track to increase 1 percent this year, Scientific American noted the 1 percent increase is “significantly less than what many observers projected earlier this year” when surging natural gas prices worldwide led to worries pollution-emitting coal use would also surge. “Just peaking global emissions is the first and easiest step on the road to solving climate change,” Zeke Hausfather, a climate researcher at the payment processing firm Stripe, stated in the report, adding that global emissions are likely to plateau in the coming years while decarbonization trends keep pace with economic growth (https://ibn.fm/LCVbh). The IEA reports the growth of renewable energy has “consistently and dramatically” outperformed nearly all expectations over the past decade, making it necessary for analysts to continually revise their projections for the future (https://ibn.fm/gYtcX). While coal consumption has increased this year, “the emissions impact has been largely offset by record setting growth in renewables,” the IEA informed Scientific American. Not only is it a sign that decarbonization policies are driving structural change, but “those changes are set to accelerate thanks to the major clean energy policy plans that have advanced around the world in recent months,” IEA Executive Director Fatih Birol stated. Correlate Infrastructure Partners is driven to help clients break down barriers to their environmental, social and governance (“ESG”) goals while demonstrating that sustainability and profitability are no longer at odds in terms of corporate aims. For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• The U.S. Federal Trade Commission is increasingly seeking to protect the online privacy rights of consumers
• The FTC recently sued data broker Kochava for brokering the geolocation details of millions of consumers
• Texas Attorney General Ken Paxton has filed suit against Google for allegedly collecting customer information without consent
• Reklaim enables users to reclaim their data – providing the option to delete it or monetize it

A poll conducted during the summer of 2021 showed that 13 percent of UK teens and 6 percent of American teens linked Instagram usage to suicidal thoughts. Even more surprising is the fact that the social media platform was seemingly privy to that knowledge all along. The extent to which Instagram parent company Meta (NASDAQ: META) allegedly knew about the harmful effects of its products and withheld that information from the public caused Senator Richard Blumenthal (D-CT) to compare the company’s tactics to those of tobacco companies in years past (https://ibn.fm/tPQr2). The allegations have also sparked a spate of legislation, with a number of senators recently approaching the Federal Trade Commission (“FTC”) to update the Children’s Online Privacy Protection Act in a move intended to oblige social media platforms to protect the confidentiality, security and integrity of data relating to minors. Reklaim (TSX.V: MYID) (OTCQB: MYIDF), a business focused on enabling consumers to reclaim their online information and monetize it, has been at the forefront of the battle to assist and empower users to establish ownership over personal data which has, in many cases, been circulating in the market unbeknownst to them. The company’s actions have encountered renewed impetus given increased focus on protecting data privacy from the FTC and its ongoing initiatives toward making online privacy a priority. The Advanced Notice of Proposed Rulemaking (“ANPR”) – opened by the FTC for public comments over the summer – is the first stage of that process, as noted by Rashida Richardson, the attorney advisor to FTC Chair Lina Khan, at AdExchanger’s Programmatic IO conference in New York City. “We have to go aggressively after [high-risk] data practices that pose the greatest risks to consumers, at least as a mitigating intervention,” Richardson said (https://ibn.fm/N8jHA). The FTC’s push was in full effect when the agency sued Idaho-based data broker Kochava for selling the geolocation data of hundreds of millions of mobile devices – data which the FTC argues could be used to track the physical location of consumers, including to and from sensitive areas such as reproductive health clinics or churches (https://ibn.fm/CfSyV). The litigation against Kochava coincides with a separate lawsuit filed by Texas AG Ken Paxton against Google for allegedly collecting and using biometric data belonging to millions of Texans without proper consent. The legal action has drawn attention both for the scale of the motion’s defendant and for the implications it could have on the behavior of other online businesses operating throughout the nation. With Reklaim, not only are consumers able to unlock the online data collected on them, they are able to preclude the data from leaking from their devices in the first place – the latter scenario being one which has long been exploited by search engines, social media platforms and online data brokers alike. Rather, should they wish, consumers are empowered to monetize their data, gaining compensation in return for providing third-party businesses with insights drawn from their online behavior. For more information, visit the company’s website at www.ReklaimYours.com. NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF